Biotech Values

[jq1234]

I am far from being an absolutist or ideologue. I believe you have to look at different situation under different circumstance differently. When someone suggested stopping a 1st in class drug in a large indication early by DSMB for primary endpoint without pre-specified interim stopping rule is a serious possibility, you have to question motive. I am not talking about you.